### Patient Details

<table>
<thead>
<tr>
<th>Name</th>
<th>DUMMY N108</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lab No.</td>
<td>153672456</td>
</tr>
<tr>
<td>A/c Status</td>
<td>P</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age</th>
<th>Gender</th>
<th>Ref By</th>
</tr>
</thead>
<tbody>
<tr>
<td>35 Years</td>
<td>Male</td>
<td>UNKNOWN</td>
</tr>
</tbody>
</table>

### Report Details

<table>
<thead>
<tr>
<th>Collected</th>
<th>29/7/2020 1:50:00PM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Received</td>
<td>29/7/2020 3:51:01PM</td>
</tr>
<tr>
<td>Collected</td>
<td>29/7/2020 1:50:00PM</td>
</tr>
<tr>
<td>Reported</td>
<td>31/7/2020 2:14:00PM</td>
</tr>
</tbody>
</table>

### TEST Conducted

- NRAS MUTATION, CODON 12, 13 & 61 #
  (PCR, Sequencing)

### Results

<table>
<thead>
<tr>
<th>Codon 12 Mutation</th>
<th>Codon 13 Mutation</th>
<th>Codon 61 Mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Detected</td>
<td>Not Detected</td>
<td>Not Detected</td>
</tr>
</tbody>
</table>

### Note

1. This result does not rule out the presence of mutation that may be below the detection limits of the assay (10% tumor).
2. The assay detects all variants of codons 12, 13 and 61
3. This is an in-house developed assay for research purposes only. Results to be interpreted in context of clinical findings, tumor sampling and other laboratory data.

### Comments

RAS mutations are commonly found in cancer tissue, causing a permanent activation of the signal transduction pathway downstream of the EGF receptor (EGFR), thus positive signaling for cell growth. Most frequent are KRAS mutations in codons 12,13 in the second (first transcribed) exon. Up to 45% of all colorectal cancer patients exhibit KRAS 12,13 mutations, while another 10-15% may have mutations in KRAS exons 3 and 4 or in the respective regions of the homologous NRAS gene.

---

Dr Anand Chandrasekaran Annan  
MD (American Board of Pathology)  
PhD (Molecular & Cellular Pathology)  
HOD - Oncopathology  

Dr Atul Thatai  
PhD, Biotechnology  
HOD Molecular Diagnostics  
NRL - Dr Lal PathLabs Ltd

---

**IMPORTANT INSTRUCTIONS**

*Test results released pertain to the specimen submitted.*  
*All test results are dependent on the quality of the sample received by the Laboratory.*  
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician.*  
*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.*  
*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.*  
*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.*  
*Test results may show interlaboratory variations.*  
*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*  
*Test results are not valid for medico legal purposes.*  
*Contact customer care Tel No. +91-11-39885050 for all queries related to test results.*

# Not in NABL scope

---

If test results are alarming or unexpected, client is advised to contact the laboratory immediately for possible remedial action.

@ Tests conducted at National Reference Lab, New Delhi, CAP (7171001), NABL (MC-2113) and ISO (FS 60411) accredited laboratory